91 related articles for article (PubMed ID: 8637220)
1. Regulation of topoisomerase II expression during the VM-26 induced differentiation of IW32 murine erythroleukemia cells.
Tan SK; Tang SJ; Wang MC; Hwang J; Wang FF
Leuk Res; 1996 Mar; 20(3):249-57. PubMed ID: 8637220
[TBL] [Abstract][Full Text] [Related]
2. Protein tyrosine phosphatase-dependent activation of beta-globin and delta-aminolevulinic acid synthase genes in the camptothecin-induced IW32 erythroleukemia cell differentiation.
Wang MC; Liu JH; Wang FF
Mol Pharmacol; 1997 Apr; 51(4):558-66. PubMed ID: 9106619
[TBL] [Abstract][Full Text] [Related]
3. Expression of c-myc proto-oncogene during podophyllotoxin induced IW32 erythroleukemia cell differentiation.
Yen YT; Wu RT; Tang SJ; Wang FF
Biochem Biophys Res Commun; 1991 Sep; 179(3):1241-6. PubMed ID: 1930169
[TBL] [Abstract][Full Text] [Related]
4. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
Chen M; Beck WT
Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
[TBL] [Abstract][Full Text] [Related]
5. Induction of IW32 erythroleukemia cell differentiation by p53 is dependent on protein tyrosine phosphatase.
Tang PP; Wang FF
Leukemia; 2000 Jul; 14(7):1292-300. PubMed ID: 10914555
[TBL] [Abstract][Full Text] [Related]
6. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
Kim R; Beck WT
Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
[TBL] [Abstract][Full Text] [Related]
7. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
Fernandes DJ; Danks MK; Beck WT
Biochemistry; 1990 May; 29(17):4235-41. PubMed ID: 2163274
[TBL] [Abstract][Full Text] [Related]
8. Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1990 Oct; 50(20):6723-30. PubMed ID: 2170008
[TBL] [Abstract][Full Text] [Related]
9. The effect of topoisomerase inhibitors on the expression of differentiation markers and cell cycle progression in human K-562 leukemia cells.
Constantinou A; Grdina D; Kiguchi K; Huberman E
Exp Cell Res; 1992 Nov; 203(1):100-6. PubMed ID: 1330653
[TBL] [Abstract][Full Text] [Related]
10. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ
Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414
[TBL] [Abstract][Full Text] [Related]
11. The topoisomerase II inhibitor VM-26 induces marked changes in histone H1 kinase activity, histones H1 and H3 phosphorylation, and chromosome condensation in G2 phase and mitotic BHK cells.
Roberge M; Th'ng J; Hamaguchi J; Bradbury EM
J Cell Biol; 1990 Nov; 111(5 Pt 1):1753-62. PubMed ID: 2172257
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
Wolverton JS; Danks MK; Granzen B; Beck WT
Cancer Res; 1992 Aug; 52(15):4248-53. PubMed ID: 1322239
[TBL] [Abstract][Full Text] [Related]
14. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines.
Matsuo K; Kohno K; Takano H; Sato S; Kiue A; Kuwano M
Cancer Res; 1990 Sep; 50(18):5819-24. PubMed ID: 2168282
[TBL] [Abstract][Full Text] [Related]
15. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
Bugg BY; Danks MK; Beck WT; Suttle DP
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7654-8. PubMed ID: 1652758
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of alpha- and beta-globin genes in erythroleukemic cell lines.
Beru N; Maples PB; Hermine O; Goldwasser E
Mol Cell Biol; 1990 Jul; 10(7):3591-5. PubMed ID: 2355917
[TBL] [Abstract][Full Text] [Related]
17. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
Chen M; Beck WT
Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
[TBL] [Abstract][Full Text] [Related]
18. Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26.
Danks MK; Qiu J; Catapano CV; Schmidt CA; Beck WT; Fernandes DJ
Biochem Pharmacol; 1994 Nov; 48(9):1785-95. PubMed ID: 7980648
[TBL] [Abstract][Full Text] [Related]
19. Enhanced expression of the DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells.
Matsuo K; Kohno K; Sato S; Uchiumi T; Tanimura H; Yamada Y; Kuwano M
Cancer Res; 1993 Mar; 53(5):1085-90. PubMed ID: 8382554
[TBL] [Abstract][Full Text] [Related]
20. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26.
Chen M; Beck WT
Cancer Res; 1995 Apr; 55(7):1509-16. PubMed ID: 7882360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
